Top 5 Drug Type | Count |
---|---|
Small molecule drug | 12 |
Diagnostic radiopharmaceuticals | 2 |
Chemical drugs | 1 |
ASO | 1 |
Synthetic peptide | 1 |
Target |
Mechanism aromatase modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SLC7A5 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism KDM1A inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date29 Mar 2024 |
Sponsor / Collaborator |
Start Date17 Aug 2022 |
Sponsor / Collaborator |
Start Date22 Apr 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
[18F]AA-7 ( SLC7A5 ) | Glioma More | Clinical |
IL-7R-targeting antibody-drug conjugates(National Cancer Center/RIKEN) ( IL-7Rα x Tubulin ) | Autoimmune Diseases More | Preclinical |
HiP-8 ( c-Met ) | Neoplasms More | Preclinical |
IM-17 | Myocardial Reperfusion Injury More | Preclinical |
S1427 ( KDM1A ) | Neoplasms More | Preclinical |